Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01839968

Enrollment

Registered

2013-04-25

Start date

2011-09-30

Completion date

2014-01-31

Last updated

2014-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Platelet Disorder

Brief summary

The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

Interventions

OTHEREx vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute coronary syndrome * Prasugrel loading dose 6-24h before inclusion

Exclusion criteria

* Clopidogrel loading dose * GPIIbIIIa use within 10 days before inclusion * Known congenital thrombopathy and/or congenital coagulation defect

Design outcomes

Primary

Measure	Time frame
Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition	within the first 6-24 hours after antiplatelet drug loading dose

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026